Biomarkers /
DUSP6
Back to Biomarkers List
Overview
DUSP6 is altered in 0.69% of all cancers with conventional glioblastoma multiforme, oligodendroglioma, thyroid gland undifferentiated (anaplastic) carcinoma, adrenal cortex carcinoma, and anaplastic astrocytoma having the greatest prevalence of alterations [3].
The most common alterations in DUSP6 are DUSP6 R40Q (0.13%), DUSP6 A191V (0.07%), DUSP6 E344K (0.07%), DUSP6 H292L (0.09%), and DUSP6 L290F (0.07%) [3].
Clinical Trials
Significance of DUSP6 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
